XFOR (X4 Pharmaceuticals) 3-1 Month Momentum %: -8.40% (As of Jul. 09, 2026)


XFOR X4 Pharmaceuticals Inc XFOR
24 GF Score
Price $3.98
! 5 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals 3-1 Month Momentum %?

X4 Pharmaceuticals XFOR +0.51% 24 3-1 Month Momentum % is -8.40% as of Jul. 09, 2026. GuruFocus rates XFOR with a GF Score™ of 24/100. The stock has 5 warning signs investors should review. Among 1,378 Biotechnology companies, X4 Pharmaceuticals ranks better than 55.44% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-09), X4 Pharmaceuticals's 3-1 Month Momentum % is -8.40%.

The industry rank for X4 Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:

XFOR's 3-1 Month Momentum % is ranked better than
55.44% of 1378 companies
in the Biotechnology industry
Industry Median: -11.025 vs XFOR: -8.40

X4 Pharmaceuticals  (NAS:XFOR) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

X4 Pharmaceuticals 3-1 Month Momentum % Related Terms

XFOR vs CMPX, LRMR, PROK: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's 3-1 Month Momentum % falls into.


XFOR
24GF Score
X4 Pharmaceuticals Inc XFOR
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals  (NAS:XFOR) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -8.40% mean?
X4 Pharmaceuticals (XFOR) has a 3-1 Month Momentum % of -8.40% as of Jul. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on X4 Pharmaceuticals and its competitors. According to the industry distribution chart, X4 Pharmaceuticals ranks #614 out of 1378 companies in the Biotechnology industry, placing it in the top 44.6%.
Is X4 Pharmaceuticals' 3-1 Month Momentum % too high?
X4 Pharmaceuticals' current 3-1 Month Momentum % is -8.40%. Based on the distribution chart, X4 Pharmaceuticals ranks #614 out of 1378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, X4 Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' 3-1 Month Momentum % compare to CMPX and LRMR?
According to the Biotechnology industry distribution chart, X4 Pharmaceuticals ranks #614 out of 1378 companies for 3-1 Month Momentum %. This puts X4 Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current 3-1 Month Momentum % is -8.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current 3-1 Month Momentum % of -8.40%. The current 3-1 Month Momentum % is -8.40%. X4 Pharmaceuticals' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current 3-1 Month Momentum % is -8.40% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score

Get the complete analysis for XFOR

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price